The difference between lxazomib and bortezomib

Ixazomib and bortezomib are both drugs used to treat multiple myeloma (Multiple Myeloma), but they differ significantly in several ways. Here's a detailed comparison of the two drugs.

1. Drug category:

Ixazomib: Ixazomib is an oral proteasome inhibitor and belongs to a new generation of therapeutic drugs. It acts on the protein degradation process within the proteasome, inhibiting the growth and reproduction of abnormal plasma cells.

Bortezomib: Bortezomib is a proteasome inhibitor, but it is an injection and needs to be given to the patient intravenously. It is a pioneer drug in the treatment of multiple myeloma and has been widely used for many years.

2. Route of administration:

Ixazomib: Ixazomib is given as an oral medication, which allows patients to take it easily at home without the need for regular trips to the hospital.

Bortezomib: Bortezomib must be given as an intravenous infusion, usually in a medical facility or hospital. This can be inconvenient for patients because it requires the supervision of a medical professional.

3. Treatment Plan:

Ixazomib: Ixazomib is often used with other drugs, such as hormones, immunomodulators, and chemotherapy drugs, to create a comprehensive treatment regimen. This combination treatment helps to improve the effectiveness of the treatment.

Bortezomib: Bortezomib can also be used in combination with other drugs, but it is most commonly used for initial treatment and relapse treatment, often in combination with other drugs such as dexamethasone (dexamethasone ).

4. Mechanism of action:

Ixazomib: Ixazomib slows down the growth and reproduction of multiple myeloma cells by inhibiting the function of the proteasome and interfering with the degradation and recycling processes of intracellular proteins.

Bortezomib: Bortezomib is also a proteasome inhibitor, but it acts on cells through a different mechanism, directly interfering with the normal function of the proteasome, leading to multiple myeloma cell death.

5. Side effects:

Ixazomib: Common side effects of ixazomib include nausea, vomiting, diarrhea, fatigue, anemia, and low platelet count. It is generally considered to be better tolerated than bortezomib.

Bortezomib: Common side effects of bortezomib include peripheral neuropathy, nausea, vomiting, diarrhea, anemia, and low platelet count. In addition, bortezomib may cause severe neurotoxicity.

6. Clinical efficacy:

Ixazomib: Ixazomib has shown efficacy in multiple myeloma in clinical trials, extending survival and improving patients' quality of life.

Bortezomib: Bortezomib is a classic drug for the treatment of multiple myeloma. It has been widely used for many years and has shown good efficacy in clinical trials.

In short, both ixazomib and bortezomib are important drugs for the treatment of multiple myeloma, but they have significant differences in administration routes, mechanisms of action, side effects and treatment options. Treatment selection will usually be based on the patient's specific condition and the recommendations of the doctor. Every patient should work closely with a medical professional to develop a treatment plan that best suits their situation.

The original drug of Ixazomib has been launched in China and has been included in medical insurance. Patients can purchase it domestically, but the price is still relatively high. The price is about 15,000 to 6,000 yuan. For specific prices and medical insurance reimbursement policies, please consult the local hospital pharmacy or medical insurance bureau. Foreign original drugs are even more expensive. The cheaper foreign ones are ixazomib generics, mainly Laotian generics. The price is more than 1,000 yuan, and the ingredients of the original drugs and generic drugs are basically the same.